‘de Novo’ repurposing of Daflon as anti-intestinal parasitic drug in experimental giardiasis

Bibliographic Information
Authors: Fahmy A.; Abuelenain G.L.; Rasheed N.; Abdou A.
Journal: Experimental Parasitology
Publisher: Academic Press Inc.
Publication Date: July 2021
Volume / Issue: Volume 226-227
Article No.: 108124
ISSN: 144894
DOI: 10.1016/j.exppara.2021.108124
Scopus: View on Scopus
PubMed: 34139241
Document Type: Article
Authors and Affiliations
Fahmy A., Parasitology Lab, Department of Immunology and Drug Evaluation, Theodor Bilharz Research Institute, Imbaba, Egypt; Abuelenain G.L., Parasitology Lab, Department of Immunology and Drug Evaluation, Theodor Bilharz Research Institute, Imbaba, Egypt; Rasheed N., Animal Health Research Institute, NRC, Giza, Egypt; Abdou A., Microbiology and Immunology Department, NRC, Giza, Egypt
Abstract
Background: There is a necessity to develop or discover an alternative drug to combat the drug resistance by Giardia duodenalis and minimize the multiple doses and frequency of the conventional drug administration. Progressive repositioning or ‘repurposing’ of drugs has become widespread due to economic circumstances and medical emergency needs. Daflon 500 mg (DFL) is a natural product used safely as a nutrient supplement and an antidiabetic drug in many European countries and the US. Objective: This study aimed at investigating the efficiency of DFL, in vivo, in a murine model as a safe alternative or co-drug for giardiasis. Materials and methods: Swiss Albino mice (n = 32) were inoculated with 1X104 Giardia cysts and assigned to four groups: One group was the infected non-treated control mice and three experimental groups that were treated differently, either with Metronidazole (MTZ), DFL, or combined therapy of DFL/MTZ. Also, eight normal mice served as a control group. All mice were sacrificed 13 days post-infection for the parasitic, histopathological, and oxidative stress analysis. Results: MTZ, DFL, and the combined therapy significantly reduced the number of trophozoites and cysts compared to their counterparts of the infected mice. The histopathological analysis of the small intestines of the mice treated with the combined therapy retained typical intestinal architecture and normal levels of malondialdehyde (MDA), superoxide dismutase (SOD), and glutathione. Conclusion: This study indicated promising actions of Daflon 500 as an anti-giardial drug, and the results demonstrated its potential effect in improving the intestinal epithelial tissue and disturbing the Giardia stages when it was taken collectively with Metronidazole. © 2021 Elsevier Inc.
Keywords
Anti-giardial; Daflon; Giardia; Histopathology; Repurposing; Animals; Antiprotozoal Agents; Diosmin; Drug Combinations; Feces; Giardiasis; Humans; Intestines; Metronidazole; Mice; Trophozoites; glutathione; malonaldehyde; superoxide dismutase; antiprotozoal agent; animal experiment; animal model; animal tissue; antiprotozoal activity; Article; combination drug therapy; controlled study; cyst (resting stage); drug efficacy; drug repositioning; drug safety; experimental parasitosis; in vivo study; male; monotherapy; mouse; nonhuman; animal; drug combination; drug effect; human; intestine; parasitology; pathology; trophozoite
Citation Information
Scopus Citations: 8
For comprehensive information about the Theodor Bilharz Research Institute (TBRI), its institutional activities, scientific and research achievements, clinical and hospital services, and the diverse expertise offered through its 22 specialized research and clinical departments, as well as opportunities for professional training, specialized workshops, and scientific conferences, readers are invited to visit the Institute’s official website.
The website provides regularly updated information on the Institute’s latest news, research activities, scientific initiatives, clinical services, institutional programs, and academic and professional opportunities.
English Website: https://www.tbri.sci.eg/en/
Arabic Website: https://www.tbri.sci.eg/ar/
Prepared and Uploaded by:
Abdalla F. Abdalla
Electronic Portal Unit
